Polypills — A Central Strategy for Improving Cardiovascular Health
- 21 January 2021
- journal article
- editorial
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 384 (3), 288-289
- https://doi.org/10.1056/nejme2033310
Abstract
The polypill concept garnered substantial attention in 2003 after the publication of a modeling analysis that proposed that the use of fixed-dose combination therapy in persons with established atherosclerotic cardiovascular disease and in all other adults 55 years of age or older could reduce disease burden by 80% or more.1 Notably, these models overestimated the effects of aspirin and folic acid and assumed full long-term adherence to the regimen. Subsequent randomized trials testing the effects of different polypills in small populations over short periods of time showed reductions in the cholesterol level and blood pressure and increases in the percentages . . .Keywords
This publication has 6 references indexed in Scilit:
- Polypill with or without Aspirin in Persons without Cardiovascular DiseaseThe New England Journal of Medicine, 2021
- Five insights from the Global Burden of Disease Study 2019The Lancet, 2020
- Implementation Strategies for Cardiovascular PolypillsJAMA, 2019
- Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trialThe Lancet, 2019
- Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseasesEmergencias, 2017
- A strategy to reduce cardiovascular disease by more than 80%BMJ, 2003